# PHARMACOLOGY OF 1-THIOCARBAMOYL-2IMIDAZOLIDINONE

> **NIH NIH R01** · CASE WESTERN RESERVE UNIVERSITY · 1987 · $172,724

## Abstract

1-Thiocarbamoyl-2-imidazolidinone (TCI) inhibits immune interferon-induced
expression of Ia antigen on cultured mouse peritoneal macrophages, a
discovery that could explain the unusual immunopharmacological effect of
TCI on cellular and humoral immunity.  Our goals now are to elucidate the
specificity and possible mechanism(s) of action of this extremely potent
agent.  Specific aims are to 1) characterize the effects of TCI on immune
interferon-induced changes in Ia expression by macrophages, 2) determine
whether TCI affects other immune interferon-induced responses and certain
immune interferon-independent induced properties of macrophages, 3)
ascertain whether TCI mediates its effects via cell surface receptors and
explore receptor interactions between TCI, immune interferon and other
relevant mediators, and 4) identify intracellular biochemical processes
that are affected by TCI alone or in combination with immune interferon
and/or other mediators.  Responses of a macrophage-like tumor cell line,
e.g. P388D1, to immune interferon and TCI will be studied; parameters
perturbed by the lymphokine and affected by TCI are most likely to relate
to the latter's mode action.  Changes in cell surface protein expression
will be monitored by immunofluorescence, radio-immunoassay and flow
cytometry.  Other macrophage functions to be examined include abililties to
generate a respiratory burst, phagocytize opsonized particles and present
antigen to target cells.  3H-TCI of high specific radioactivity will be
used to study cellular transport of TCI, identify putative TCI "receptors"
in whole cells and membrane preparations, and elucidate binding
interactions between TCI, immune interferon and/or other mediators.  This
research should provide basic information about the immunomodulatory
actions of immune interferon and TCI as well as suggest appropriate
clinical applications for TCI.

## Key facts

- **NIH application ID:** 3129525
- **Project number:** 5R01AI020044-04
- **Recipient organization:** CASE WESTERN RESERVE UNIVERSITY
- **SAM.gov UEI:** HJMKEF7EJW69
- **Principal Investigator:** LESLIE T. WEBSTER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $172,724
- **Award type:** 5
- **Project period:** 1984-09-01 → 1988-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3129525

## Citation

> US National Institutes of Health, RePORTER application 3129525, PHARMACOLOGY OF 1-THIOCARBAMOYL-2IMIDAZOLIDINONE (5R01AI020044-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3129525. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*